Zymeworks (ZYME) Non-Current Assets (2021 - 2026)
Zymeworks recorded quarterly Non-Current Assets of $92.5 million in Q1 2026, down 5.34% quarter-over-quarter from $97.8 million in Q4 2025, and down 22.28% year-over-year from $119.1 million in Q1 2025.
Zymeworks' Non-Current Assets history runs 6 years deep, the most recent figure standing at $92.5 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 22.28% year-over-year to $92.5 million; the TTM figure through Mar 2026 stood at $408.1 million (down 26.76% YoY), while the FY2025 annual figure was $97.8 million, down 39.89% from the prior year.
- Non-Current Assets came in at $92.5 million for Q1 2026 at Zymeworks, down from $97.8 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $181.7 million in Q3 2023 to a low of $92.5 million in Q1 2026.
- A 5-year average of $136.3 million and a median of $132.1 million in 2024 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets soared 65.8% in 2023 and plunged 39.89% in 2025, its largest moves.
- Zymeworks' Non-Current Assets stood at $104.0 million in 2022, then surged by 61.46% to $168.0 million in 2023, then declined by 3.16% to $162.6 million in 2024, then slumped by 39.89% to $97.8 million in 2025, then dropped by 5.34% to $92.5 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $92.5 million, $97.8 million, and $105.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - | 92.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92.54 Mn |
| Dec 31, 2025 | 97.76 Mn |
| Sep 30, 2025 | 105.56 Mn |
| Jun 30, 2025 | 112.26 Mn |
| Mar 31, 2025 | 119.06 Mn |
| Dec 31, 2024 | 162.64 Mn |
| Sep 30, 2024 | 143.38 Mn |
| Jun 30, 2024 | 132.14 Mn |
| Mar 31, 2024 | 159.93 Mn |
| Dec 31, 2023 | 167.95 Mn |
| Sep 30, 2023 | 181.73 Mn |
| Jun 30, 2023 | 181.72 Mn |
| Mar 31, 2023 | 174.37 Mn |
| Dec 31, 2022 | 104.02 Mn |
| Sep 30, 2022 | 109.61 Mn |
| Dec 31, 2021 | 100.91 Mn |